FIGURE 1


LNCaP (dosed day 33)
Tumor Volume (mm3)
1500
1000
500
0
30
40
50
60
70
Days after cell implantation
Vehicle
ARXαPSMA(A116)-NCA1 1 mg/kg
ARXαPSMA(A116)-NCA1 3 mg/kg
ARXαPSMA(A116)-NCA1 10 mg/kg
Unconjugated ARX-αPSMA(A116) 10 mg/kg

FIGURE 2


LNCaP Body Weight
Body Weight (g)
34
32
30
28
26
24
30
40
50
60
70
Days after cell implantation
Vehicle
ARXαPSMA(A116)-NCA1 1 mg/kg
ARXαPSMA(A116)-NCA1 3 mg/kg
ARXαPSMA(A116)-NCA1 10 mg/kg
Unconjugated ARX-αPSMA(A116) 10 mg/kg

FIGURE 3A


LNCaP, PSMA J591VK-Tubulin inhibitor
%media control
140
120
100
80
60
40
20
0
0.0001
0.001
0.01
0.1
1
10
100
log[nM]
Dolastatin free drug IC50=0.1nM
antiPSMA-ADC IC50=0.4nM

FIGURE 3B


MDA-PCa-2, PSMA J591VK-Tubulin inhibitor
%media control
140
120
100
80
60
40
20
0
0.0001
0.001
0.01
0.1
1
10
100
log[nM]
Dolastatin free drug IC50=0.1nM
antiPSMA-ADC IC50=0.3nM

FIGURE 4


PC-3, Viability Assay, antiPSMA-NCA1
%media control
140
120
100
80
60
40
20
0.0001
0.001
0.01
0.1
1
10
100
log[nM]
Dolastatin free drug IC50=0.1nM
antiPSMA VK NCA1 IC50>30nM

FIGURE 5A


LNCaP, PSMAJ591VK-DNA alkylator
%media control
120
100
80
60
40
20
0
0.0001
0.001
0.01
0.1
1
10
100
log[nM]
Dolastatin free drug IC50=0.1nM
DNA alkylator free drug IC50=0.2nM
antiPSMA-ADC IC50=0.3nM

FIGURE 5B


MDA-PCa-2b, PSMAJ591VK-DNA alkylator
%media control
140
120
100
80
60
40
20
0
-20
0.0001
0.001
0.01
0.1
1
10
100
log[nM]
Dolastatin free drug IC50=0.1nM
DNA alkylator free drug IC50=0.1nM
antiPSMA-ADC IC50=0.2nM

FIGURE 6


PC3, antiPSMAJ591VK-Duo328
120
100
80
60
40
20
0
%media control
0.0001
0.001
0.01
0.1
1
10
100
log[nM]
Duocarmycin free drug IC50=0.1nM
antiPSMAJ591-VK-Duocarmycin IC50>30nM